- Home
- Companies
- usa virginia
- pre clinical effectiveness case study
Refine by
Pre Clinical Effectiveness Case Study Suppliers Serving Usa Virginia
75 companies found
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ ...
based inGolden, COLORADO (USA)
At Vitro Biopharma, our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market, and ultimately, to address well-established multi-billion-dollar ...
based inFoster City, CALIFORNIA (USA)
PointCross Life Sciences is a wholly-owned subsidiary of PointCross Inc. We are a global technology company providing the life sciences industry with solutions in big data analytics, management, visualization, and warehousing. Our offerings reduce ...
based inMunich, GERMANY
AdjuCor is a medical devices company based in Germany. Minimally invasive. Maximally effective. BEAT is the most human solution to treating heart failure. Just like a skin, it covers the diseased heart and supports it in its function. Adaptable to ...
based inMountain View, CALIFORNIA (USA)
ClearLight Biotechnologies provides contract research and development services to pharmaceutical companies who seek to improve the efficacy of potential drug candidates. The company provides pharmaceutical, biotechnology, and academic researchers ...
based inLa Jolla, CALIFORNIA (USA)
Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
based inLowell, MASSACHUSETTS (USA)
Diagnosys is an inventor-owned private company devoted to the field of ophthalmic electrophysiology. Founded in 1983 as Doran Instruments, this company invented the Maculoscope, a focal ERG system that is the predicate device for most of the ...
based inBozeman, MONTANA (USA)
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections. Microbion is dedicated to developing ...
Cystic Fibrosis (CF) lung disease, which is estimated to affect more than 30,000 in the US and 70,000 worldwide1, is characterized by chronic bacterial infection and severe inflammation that leads to progressive deterioration in lung function. ...
based inDurham, NORTH CAROLINA (USA)
Altis Biosystems’ mission is to develop, manufacture, and sell innovative services and research tools to reduce costs and accelerate drug development with in vitro platforms that more accurately reflect native human biology. Altis Biosystems is a ...
RepliGut is a unique, human stem cell-derived platform that recreates the intestinal epithelium in a continuous layer of stem and differentiated cells. RepliGut® can be purchased as a product, or Altis Biosystems can provide the services you ...
based inNorth Brunswick, NEW JERSEY (USA)
Ascendia Pharmaceuticals specializes in the invention and development of specialty pharmaceutical products and novel formulation technologies. We provide formulation, analytical, and manufacturing services to pharmaceutical companies, working ...
Ascendia specializes in the development of market suitable formulations for poorly water soluble drug substances. Based on the pre-formulation data package and the delivery requirements for the product, we recommend a comprehensive formulation ...
based inUnion City, CALIFORNIA (USA)
Fibralign is an award-winning, commercial-stage, Stanford-spinout that designs, develops and produces novel therapeutic medical devices to address major unmet medical needs. Based in the San Francisco Bay Area, the company’s team has established GMP ...
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means ...
based inNorcross, GEORGIA (US) (USA)
Xstrahl is a prominent global provider specializing in the development and delivery of superficial radiation therapy devices and advanced preclinical radiation research systems. The company is actively engaged in connecting experts to further the ...
The Small Animal Radiation Research Platform (SARRP) by Xstrahl is a cutting-edge system designed for preclinical radiation research. SARRP is notable for its ability to replicate modern radiation therapy techniques within a laboratory setting, ...
based inMerelbeke, BELGIUM
Ziphius Vaccines is named after the rare dolphin Ziphius cavirostris. This dolphin is most known for undertaking the deepest and longest dives recorded. Ziphius' mission is to reduce the global impact of infectious diseases on global health care by ...
based inMilpitas, CALIFORNIA (USA)
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT and other gene editing technologies developed after 12 ...
based inMalvern, PENNSYLVANIA (USA)
TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to ...
OviTex, a Reinforced Tissue Matrix, was designed in collaboration with surgeons and healthcare providers to address the unmet clinical and financial needs in hernia repair and abdominal wall reconstruction. Our solutions are comprised of polymer ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
PLA2R-CAART is being developed to treat patients with PLA2R-associated membranous nephropathy (MN), a B cell-mediated autoimmune disease that affects the kidneys. B cells produce autoantibodies, which are believed to form immune ...
based inBellevue, WASHINGTON (USA)
EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®), to provide safe and effective ...
Indolor Therapeutics is feasibility (phase I) trial ready for the treatment of acute and chronic pain by the application of specific pain-managing ulRFE fields, another expression of EMulate’s Therapeutic ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...